Vol 41, No 10 (October 2020): Acta Pharmacologica Sinica

Review Article

Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors   Pages (1263–1271)
Si-yu Ren, Zhen-zhen Wang, Yi Zhang, Nai-hong Chen
Drug development in targeting ion channels for brain edema   Pages (1272–1288)
Zheng-wei Luo, Andrea Ovcjak, Raymond Wong, Bao-xue Yang, Zhong-ping Feng, Hong-shuo Sun
Growth factors-based therapeutic strategies and their underlying signaling mechanisms for peripheral nerve regeneration   Pages (1289–1300) Open
Rui Li, Duo-hui Li, Hong-yu Zhang, Jian Wang, Xiao-kun Li, Jian Xiao
Mitochondrial Ca2+ regulation in the etiology of heart failure: physiological and pathophysiological implications   Pages (1301–1309)
Hai-xia Xu, Su-mei Cui, Ying-mei Zhang, Jun Ren
Phase separation as a therapeutic target in tight junction- associated human diseases   Pages (1310–1313)
Shuang Sun, Jun Zhou

Article

Gastrodin protects H9c2 cardiomyocytes against oxidative injury by ameliorating imbalanced mitochondrial dynamics and mitochondrial dysfunction   Pages (1314–1327)
Qiao-qiao Cheng, Yu-wei Wan, Wei-min Yang, Meng-hua Tian, Yu-chuan Wang, Hai-yan He, Wei-dong Zhang, Xuan Liu
High-throughput screening campaign identifies a small molecule agonist of the relaxin family peptide receptor 4   Pages (1328–1336)
Guang-yao Lin, Lin Lin, Xiao-qing Cai, An-tao Dai, Yue Zhu, Jie Li, Qing Liu, De-hua Yang, Ross A. D. Bathgate, Ming-wei Wang
Free fatty acid receptor 4 (FFA4) activation ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis by increasing regulatory T cells in mice   Pages (1337–1347)
So-Eun Son, Soo-Jin Park, Jung-Min Koh, Dong-Soon Im
Fisetin alleviates sepsis-induced multiple organ dysfunction in mice via inhibiting p38 MAPK/MK2 signaling   Pages (1348–1356)
Hai-feng Zhang, Hai-bo Zhang, Xue-ping Wu, Ya-ling Guo, Wei-dong Cheng, Feng Qian
Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells   Pages (1357–1365)
Le-le Zhang, Jun Lu, Rui-qi Liu, Min-juan Hu, Yi-ming Zhao, Sheng Tan, Shu-yuan Wang, Bo Zhang, Wei Nie, Yu Dong, Hua Zhong, Wei Zhang, Xiao-dong Zhao, Bao-hui Han
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer   Pages (1366–1376)
Xiao-yun Liu, Zi-tao Guo, Zhen-dong Chen, Yi-fan Zhang, Jia-lan Zhou, Yong Jiang, Qian-yu Zhao, Xing-xing Diao, Da-fang Zhong